ClinicalTrials.gg
Status unknownNCT01918241PEG-rhG-CSFUpdated Nov 10, 2015

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

A Phase 2 interventional study of pegfilgrastim,30mcg/kg and pegfilgrastim, 60mcg/kg in Neutropenia, sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd.,. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-10.

Sponsored by Hangzhou Jiuyuan Gene Engineering Co. Ltd., · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Planned enrollment
9th of 28
200 · median 121
Started
2013
with 1 other
Phase 2
14 of 33
none open now
Registered
23rd of 33
by date
Lead sponsor
2 of 33
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 9th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 2, and was the 23rd registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.

Read the detailed description

The study consist of a screening period and a 21-day chemotherapy period of the same chemotherapy treatment cycle(s).Screening the subjects according to the inclusion criteria and exclusion criteria before 2 weeks of chemotherapy, and the screening successfully patients will be eligible for this study. The 1st chemotherapy treatment cycle defined as subjects screening period, subjects will be treated with the TC or EC regimen on the 1st day, aiming to screen out Chemotherapy-induced Neutropenia of ≥grade 3 (ANC\<1.0×10\^9/L) who can have the eligible to enter the 2nd chemotherapy treatment cycle, otherwise to quit the study. On the 1st day in cycle 2, subjects will be treated with the same regimen as the 1st chemotherapy treatment cycle, and be received the test drugs or controlled from the 3rd day to observe the efficacy and safety.

【Primary Outcome Measures】:

  • Duration of ≥grade 3 neutropenia in cycle 2

【Secondary Outcome Measures】:

  • Incidence of ≥grade 3 neutropenia induce;
  • Incidence of febrile neutropenia;
  • Duration for ANC from chemotherapy finished to ANC nadir and the minimum ANC ;
  • Duration for ANC recovery from nadir to 2.0×10\^9/L.
03

Conditions studied

  • Neutropenia

Browse trials for

Keywords

  • Pegylation
  • G-CSF
  • Efficacy
  • Satety
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age:18-70 years;
  • Comfirmed advanced tumor patients by histopathological with regarding initialtreatment or adjuvant, or chemotherapy,suitable for chemotherapy with canboplatin combined with taxol or cyclophosphamide combined with pharmorubicin in the opinion of the investigator;
  • Performance status(EOCG)≤1;
  • Normal human peripheral blood are eligible for the chemotherapy, WBC≥3,500 per cubic millilit, ≥ 1,500 per cubic milliliter, ≥ 100,000 per cubic milliliter;
  • Normal examination;
  • Without liver patients: the level of 、、AST were in the 2.5 times of upper normal limit; Liver metastasis patients: the level of ALT、TBIL、AST were in the 5 times of upper normal limit;
  • Renal function indices:the level of Cr、BUN were bothe in the 1.25 times of upper normal limit;
  • >3 months;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Be treated with radiotherapy in nearly 4 weeks(not included local radiotherapy for the bone );
  • Be treated with hemopoietic stem cell transplantation or bone marrow transplant;
  • Not adequately controlled infections(e.g. ≥ 12,000 per cubic milliliter,temperature > 38.2℃)
  • Evidence of metastatic disease in bone marrow,or with other malignant tumors (not included cured basal cell carcinoma and endometrial carcinoma);
  • Subjects with unconscious or symptomatic ;
  • Subjects with serious heart、liver and renal disease;
  • Subjects with serious diabetes or poor control in glycemia;
  • Pregnant or breast-feeding period females;
  • Be treated with antibiotics in 72 hours or currently being treated with antibiotics;
  • Treated with PEG-rhG-CSF in past;
  • Participated 3 or more than 3 clinical trials in nearly a year(as subjects) or any clinical trials in nearly 3 months;
  • Allergic disorders or allergies subjects or known to filgrastim or any of the products to be administered during dosing;
  • Suspected or comfirmed evidences of drug、treatment of drugs or alcohol abused;
  • Serious Neurological disorders that would affect the consent or observation;
  • Other conditions which in the opinion of the investigator preclude enrollment into the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    pegfilgrastim,30mcg/kg

    On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.

    Drug: pegfilgrastim,30mcg/kg

  • Experimental
    pegfilgrastim, 60mcg/kg

    On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.

    Drug: pegfilgrastim, 60mcg/kg

  • Experimental
    pegfilgrastim,100mcg/kg

    On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.

    Drug: pegfilgrastim, 100mcg/kg

  • Experimental
    filgrastim,5mcg/kg

    On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10\^9/L, but at least 7 days.

    Drug: filgrastim, 5mcg/kg

Interventions

  • Drugpegfilgrastim,30mcg/kg

    Drug page: Pegfilgrastim

    Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.

    Also known as: PEG-rhG-CSF,30mcg/kg

  • Drugpegfilgrastim, 60mcg/kg

    Drug page: Pegfilgrastim

    Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

    Also known as: PEG-rhG-CSF,60mcg/kg

  • Drugpegfilgrastim, 100mcg/kg

    Drug page: Pegfilgrastim

    Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

    Also known as: PEG-rhG-CSF,100mcg/kg

  • Drugfilgrastim, 5mcg/kg

    Drug page: Filgrastim

    At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.

    Also known as: rhG-CSF,5mcg/kg

06

What researchers measure

Primary outcomes

  1. Duration of ≥grade 3 neutropenia in cycle 2

    Time frame: 21 days

Secondary outcomes

  1. change of Neutropenia and ANC in cycle 2

    1. Incidence of ≥grade 3 neutropenia; 2. Incidence of febrile neutropenia; 3. Measurement the duration from chemotherapy finished to the ANC reached the nadir and the value of ANC's nadir; 4. Time to ANC recovery,the time from chemotherapy administration until the patient's ANC increasd to 2.0\*109/L after the expected nadir

    Time frame: 21 days

07

Study locations

1 of 1 sites recruiting
  • Cancer Institute and Hospital, CAMS
    Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013 and a primary completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2013
First posted
Aug 7, 2013
Start
Jul 2013
Primary completionEst.
Jan 2016
Last update
Nov 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01918241
Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiangsu Cancer Institute & Hospital, The First Affiliated Hospital with Nanjing Medical University, Wuhan TongJi Hospital, The Affiliated Hospital of Inner Mongolia Medical University, Shandong Cancer Hospital and Institute, Changsha Central Hospital, Yangzhou No.1 People's Hospital, Subei People's Hospital of Jiangsu Province
Responsible party
Sponsor
First posted
Aug 7, 2013
Start date
Jul 2013
Primary completion
Jan 2016 (estimated)
Last update
Nov 10, 2015

Study contacts

Yan Qin, M.D.
Contact
010-8778-8507
Yuankai Shi
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegfilgrastim · Filgrastim

Start the discussion